KR100286624B1 - 치환된 피리미딘 및 이의 제조방법 - Google Patents

치환된 피리미딘 및 이의 제조방법 Download PDF

Info

Publication number
KR100286624B1
KR100286624B1 KR1019920019580A KR920019580A KR100286624B1 KR 100286624 B1 KR100286624 B1 KR 100286624B1 KR 1019920019580 A KR1019920019580 A KR 1019920019580A KR 920019580 A KR920019580 A KR 920019580A KR 100286624 B1 KR100286624 B1 KR 100286624B1
Authority
KR
South Korea
Prior art keywords
compound
formula
carbon atoms
methyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920019580A
Other languages
English (en)
Korean (ko)
Other versions
KR930007949A (ko
Inventor
왓슨 엘링보이 존
니케이도 마들렌
프램로즈 바글리 지한
Original Assignee
이곤 이 버그
아메리칸 홈 푸로닥츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/782,025 external-priority patent/US5149699A/en
Priority claimed from GB9207560A external-priority patent/GB2265899A/en
Priority claimed from US07/901,485 external-priority patent/US5256654A/en
Application filed by 이곤 이 버그, 아메리칸 홈 푸로닥츠 코포레이션 filed Critical 이곤 이 버그
Publication of KR930007949A publication Critical patent/KR930007949A/ko
Application granted granted Critical
Publication of KR100286624B1 publication Critical patent/KR100286624B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019920019580A 1991-10-24 1992-10-23 치환된 피리미딘 및 이의 제조방법 Expired - Fee Related KR100286624B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US07/782,025 US5149699A (en) 1991-10-24 1991-10-24 Substituted pyridopyrimidines useful as antgiotensin II antagonists
US07/782,025 1991-10-24
US7/782,025 1991-10-24
GB9207560A GB2265899A (en) 1992-04-07 1992-04-07 Substituted pyrimidines
GB9207560.5 1992-04-07
US07/901,485 US5256654A (en) 1991-10-24 1992-06-25 Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines useful as angiotensin II antagonists
US07/901,485 1992-06-25
US7/901,485 1992-06-25

Publications (2)

Publication Number Publication Date
KR930007949A KR930007949A (ko) 1993-05-20
KR100286624B1 true KR100286624B1 (ko) 2001-05-02

Family

ID=27266132

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920019580A Expired - Fee Related KR100286624B1 (ko) 1991-10-24 1992-10-23 치환된 피리미딘 및 이의 제조방법

Country Status (21)

Country Link
EP (1) EP0539086B1 (enExample)
JP (1) JP3240192B2 (enExample)
KR (1) KR100286624B1 (enExample)
CN (2) CN1039324C (enExample)
AT (1) ATE161537T1 (enExample)
AU (1) AU653635B2 (enExample)
CA (1) CA2080705C (enExample)
DE (1) DE69223734T2 (enExample)
DK (1) DK0539086T3 (enExample)
ES (1) ES2111617T3 (enExample)
FI (1) FI103971B1 (enExample)
GR (1) GR3025926T3 (enExample)
HK (1) HK1003031A1 (enExample)
HU (2) HU218786B (enExample)
IL (1) IL103436A (enExample)
LV (1) LV12047B (enExample)
NO (1) NO301275B1 (enExample)
SG (1) SG47626A1 (enExample)
SK (1) SK322192A3 (enExample)
TW (1) TW226375B (enExample)
UA (1) UA27748C2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395341T1 (de) * 1991-11-18 2008-05-15 Du Pont 2-(2'-triphenylmethyl-2'h-tetrazol-5'- yl)phenylborsäure als zwischenprodukt zur synthese von a ii receptorenantagonisten
DE69415706T2 (de) * 1993-03-24 1999-05-20 American Home Products Corp., Madison, N.J. Substituierte Pyridopyrimidine als Antihypertensiva
DE69507887T2 (de) * 1994-09-20 1999-06-17 Wakunaga Seiyaku K.K., Osaka Verfahren zur herstellung von n-biphenylmethylthiadiazolin derivaten oder deren salzen sowie dafür benötigte zwischen verbindungen
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
BRPI0516128A (pt) 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
EP1749828A1 (en) 2005-08-04 2007-02-07 Farmaprojects S.L. Process for preparing an angiotensin II receptor antagonist
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
HUE025599T2 (en) * 2007-06-07 2016-05-30 Sigma Tau Ind Farmaceuti 5ß, 14β-androstane derivatives for treating diseases caused by organ fibrosis
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2013090196A1 (en) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Combinations of azilsartan and chlorthalidone for treating hypertension black patients
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
US5100897A (en) * 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
EP0415886A3 (en) * 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
EP0515535A4 (en) * 1990-02-13 1996-01-17 Merck & Co Inc Angiotensin ii antagonists incorporating a substituted benzyl element
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
US5149699A (en) * 1991-10-24 1992-09-22 American Home Products Corporation Substituted pyridopyrimidines useful as antgiotensin II antagonists

Also Published As

Publication number Publication date
HU9203161D0 (en) 1992-12-28
JP3240192B2 (ja) 2001-12-17
FI103971B (fi) 1999-10-29
FI924397A0 (fi) 1992-09-30
FI103971B1 (fi) 1999-10-29
NO924121L (no) 1993-04-26
AU653635B2 (en) 1994-10-06
CN1175414A (zh) 1998-03-11
SK280292B6 (sk) 1999-11-08
IL103436A (en) 1996-03-31
UA27748C2 (uk) 2000-10-16
NO301275B1 (no) 1997-10-06
SG47626A1 (en) 1998-04-17
CN1072682A (zh) 1993-06-02
EP0539086B1 (en) 1997-12-29
GR3025926T3 (en) 1998-04-30
EP0539086A3 (en) 1993-06-16
HU211915A9 (en) 1996-01-29
HK1003031A1 (en) 1998-09-30
KR930007949A (ko) 1993-05-20
LV12047B (en) 1998-08-20
TW226375B (enExample) 1994-07-11
JPH05222039A (ja) 1993-08-31
DK0539086T3 (da) 1998-02-02
LV12047A (lv) 1998-05-20
CN1039324C (zh) 1998-07-29
SK322192A3 (en) 1999-11-08
HUT62893A (en) 1993-06-28
ATE161537T1 (de) 1998-01-15
CA2080705C (en) 2002-12-03
DE69223734D1 (de) 1998-02-05
EP0539086A2 (en) 1993-04-28
FI924397L (fi) 1993-04-25
DE69223734T2 (de) 1998-04-16
IL103436A0 (en) 1993-03-15
ES2111617T3 (es) 1998-03-16
AU2607992A (en) 1993-04-29
HU218786B (hu) 2000-12-28
CA2080705A1 (en) 1993-04-25
NO924121D0 (no) 1992-10-23

Similar Documents

Publication Publication Date Title
KR100286624B1 (ko) 치환된 피리미딘 및 이의 제조방법
US5149699A (en) Substituted pyridopyrimidines useful as antgiotensin II antagonists
HK1003031B (en) Condensed pyrimidine derivatives and their use as angiotensine ii antagonists
KR100251822B1 (ko) 고혈압치료제로서의 치환된 피리도피리미딘 및 이를 포함하는 약제학적 조성물
CS110591A2 (en) Pyridone derivatives, method of their production and application
EP0481614A1 (en) Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
SI9200095A (en) Heterocyclic derivatives
WO2013052395A1 (en) 1,3-substituted azetidine pde10 inhibitors
AU2024290864A1 (en) Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof
KR20070038498A (ko) 화합물
US5256654A (en) Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines useful as angiotensin II antagonists
JP2864292B2 (ja) イミダゾール誘導体およびその製造方法
EP0618207B1 (en) Substituted pyridopyrimidines as antihypertensives
GB2265899A (en) Substituted pyrimidines
US6096754A (en) N-3 substituted pyrimidin-4-ones with AII antagonistic activity
WO1994000450A1 (en) Chromanderivatives as angiotensin ii antagonists
JPH05155862A (ja) アンジオテンシンｉｉ拮抗薬−含窒素異項環化合物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20031230

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20050117

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20050117

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000